miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL

Tumor Biology

Volumn 37, Issue 2, 2016, Pages 2497-2507

  Chen, Lin ^a   Guan, Haitao ^a   Gu, Chunyan ^a   Cao, Yali ^a   Shao, Jianguo ^a   Wang, Feng ^b  

^a The Third People s Hospital of Nantong City   (China)

^b NANTONG UNIVERSITY   (China)

Author keywords

Apoptosis; APRIL; Cell cycle; Cell proliferation; Hepatocellular carcinoma; miR 383

Indexed keywords

APRIL PROTEIN; MICRORNA; MICRORNA 383; UNCLASSIFIED DRUG; MESSENGER RNA; MIRN383 MICRORNA, HUMAN; TNFSF13 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TUMOR VOLUME; UPREGULATION; GENETICS; HEP-G2 CELL LINE; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; RNA, MESSENGER; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84942054725     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4071-1     Document Type: Article

References (31)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Tabrizian P, Roayaie S, Schwartz ME. Current management of hepatocellular carcinoma. World J Gastroenterol. 2014;20(30):10223–37.
3. Mikhail S, Cosgrove D, Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives. Expert Rev Anticancer Ther. 2014;14(10):1205–18.
4. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63(5):844–55.
5. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(15):4115–27.
6. Wahid F, Khan T, Kim YY. MicroRNA and diseases: therapeutic potential as new generation of drugs. Biochimie. 2014;104:12–26.
7. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol. 2013;774:1–20.
8. Li X, Yang W, Lou L, Chen Y, Wu S, Ding G. microRNA: a promising diagnostic biomarker and therapeutic target for hepatocellular carcinoma. Dig Dis Sci. 2014;59(6):1099–107.
9. Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M. Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther. 2013;6:1167–78.
10. Li KK, Pang JC, Lau KM, Zhou L, Mao Y, Wang Y, et al. MiR-383 is downregulated in medulloblastoma and targets peroxiredoxin 3 (PRDX3). Brain Pathol. 2013;23(4):413–25.
11. Lian J, Tian H, Liu L, Zhang XS, Li WQ, Deng YM, et al. Downregulation of microRNA-383 is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation by targeting IRF1. Cell Death Dis. 2010;1:e94.
12. He Z, Cen D, Luo X, Li D, Li P, Liang L, et al. Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor. Med Oncol. 2013;30(2):557.
13. Wang F, Chen L, Ni H, Wang G, Ding W, Cong H, et al. APRIL depletion induces cell cycle arrest and apoptosis through blocking TGF-β1/ERK signaling pathway in human colorectal cancer cells. Mol Cell Biochem. 2013;383(1–2):179–89.
14. Garcia-Castro A, Zonca M, Florindo-Pinheiro D, Carvalho-Pinto CE, Cordero A, Gutierrez Del Burgo B, et al. APRIL promotes breast tumor growth and metastasis and is associated with aggressive basal breast cancer. Carcinogenesis. 2015;36(5):574–84.
15. Mhawech-Fauceglia P, Allal A, Odunsi K, Andrews C, Herrmann FR, Huard B. Role of the tumour necrosis family ligand APRIL in solid tumour development: retrospective studies in bladder, ovarian and head and neck carcinomas. Eur J Cancer. 2008;44(15):2097–100.
16. Planelles L, Medema JP, Hahne M, Hardenberg G. The expanding role of APRIL in cancer and immunity. Curr Mol Med. 2008;8(8):829–44.
17. Rasool M, Rashid S, Arooj M, Ansari SA, Khan KM, Malik A, et al. New possibilities in hepatocellular carcinoma treatment. Anticancer Res. 2014;34(4):1563–71.
18. Boye A, Yang Y. Hepatic MicroRNA orchestra: a new diagnostic, prognostic and theranostic tool for hepatocarcinogenesis. Mini Rev Med Chem. 2014;14(10):837–52.
19. D’Anzeo M, Faloppi L, Scartozzi M, Giampieri R, Bianconi M, Del Prete M, et al. The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment. Molecules. 2014;19(5):6393–406.
20. Tan YL, Chen WN. MicroRNAs as therapeutic strategy for hepatitis B virus- associated hepatocellular carcinoma: current status and future prospects. World J Gastroenterol. 2014;20(20):5973–86.
21. Hung CH, Chiu YC, Chen CH, Hu TH. MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Biomed Res Int. 2014;2014:486407.
22. Su ZX, Zhao J, Rong ZH, Geng WM, Wu YG, Qin CK. Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma. Diagn Pathol. 2014;9:47.
23. Wang WY, Zhang HF, Wang L, Ma YP, Gao F, Zhang SJ, et al. High expression of microRNA-130b correlates with poor prognosis of patients with hepatocellular carcinoma. Diagn Pathol. 2014;9:160.
24. Zhang Z, Zheng W, Hai J. MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis. Med Oncol. 2014;31(6):984.
25. Chen P, Zhao X, Ma L. Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;383(1–2):49–58.
26. Wang F, Chen L, Ding W, Wang G, Wu Y, Wang J, et al. Serum APRIL, a potential tumor marker in pancreatic cancer. Clin Chem Lab Med. 2011;49(10):1715–9.
27. Zhi X, Tao J, Xiang G, Cao H, Liu Z, Yang K, et al. APRIL induces cisplatin resistance in gastric cancer cells via activation of the NF-κB pathway. Cell Physiol Biochem. 2015;35(2):571–85.
28. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188(6):1185–90.
29. Wang F, Ding W, Wang J, Jing R, Wang X, Cong H, et al. Identification of microRNA-target interaction in APRIL-knockdown colorectal cancer cells. Cancer Gene Ther. 2011;18(7):500–9.
30. Moreaux J, Veyrune JL, De Vos J, Klein B. APRIL is overexpressed in cancer: link with tumor progression. BMC Cancer. 2009;9:83.
31. Wang G, Wang F, Ding W, Wang J, Jing R, Li H, et al. APRIL induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway. PLoS One. 2013;8(1):e55298.